Three Phase II Studies Evaluate the Combination Of REVLIMID And Rituximab In Patients With Indolent Non-Hodgkin's Lymphoma

Celgene International Sarl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non- Hodgkin's lymphoma (NHL) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.